Evotec AG : Q3 2018: Another strong quarter that beat our expectations and consensus
>Q3 2018 results ahead of expectations - Evotec published Q3 2018 results today (13 Nov), which beat both our estimates and consensus. Revenue was up 42% yoy to € 96m (Oddo BHFe: € 84m; cons.: € 91.5m). Adj. EBITDA soared to € 30.1m (Oddo BHFe: c.€ 22m; cons.: € 19.9m) from € 13.3m Q3 2017, largely driven by a $ 6m one-time payment from Celgene. The solid 42% revenue growth was driven by a strong base business, the Aptuit contribution, and high milestone payments. Ac...Evotec is a holding company engaged as a drug discovery solutions company providing drug discovery capabilities to pharmaceutical and biotechnology companies as well as to academic institutions. These drug discovery solutions are provided in form of fee-for service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Co. is primarily involved in the areas of neuroscience, pain, metabolic diseases, oncology and inflammation. Co. provides its drug discovery activities under the banners of EVT Execute, EVT Integrate and EVT Innovate. Co.'s operations are divided into two segments: EVT Execute and EVT Innovate.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.